 In its Q1 earnings release, Kymera Therapeutics Inc NASDAQ: KYMR announced the selection of the equivalent of 100 mg, in the fed state, as the dose for the Phase 1 patient cohort Part C. The cohort is expected to enroll up to 20 patients with hidradenitis suppurativa HS and atopic. 